Director dealings: Roquefort Therapeutics director raises stake

(Sharecast News) - Roquefort Therapeutics revealed on Monday that interim managing director Darrin Disley had acquired 5.0m ordinary shares in the London-listed material biotech company. Disley, who joined Roquefort in September 2022, purchased the shares on Friday at an average price of 1.70p each, for a total value of £85,000.

As a result of the transaction, Disley now holds a beneficial interest in 7.02m ordinary Roquefort shares, representing approximately 4.46% of Roquefort's issued share capital.

As of 1530 GMT, Roquefort shares were up 1.29% at 1.92p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Roquefort Therapeutics (ROQ) Director name: Disley,Dr Darrin Amount purchased: 5,000,000 @ 170.00p Value: £85,000

Mobius Investment Trust (MMIT) Director name: Dyer Bartlett ,Diana Amount purchased: 21,469 @ 137.50p Value: £29,519.88

Grainger (GRI) Director name: Fraser,Simon Amount purchased: 15,000 @ 183.00p Value: £27,450.00

Paypoint (PAY) Director name: Harding,Rob Amount purchased: 1,924 @ 519.00p Value: £9,985.56

Top Director Sells